Skip navigation
Home
Menu
Menu
Study
Student life
Research and innovation
Global
About us
Staff
Students
Search the site
Centre of Excellence for Long-acting Therapeutics
Menu
About us
LONGEVITY
HALo
Nanotherapeutics Hub
Teoreler
PKRxiv
LAPaL
Blog
News
Events
Contact us
News
MSF to roll out injectable HIV prevention drug in southern Africa
29 November 2024
Long-Acting Drugs Market Revolutionizing Therapeutics with Sustained-Release Innovations and Emerging Opportunities
29 November 2024
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
29 November 2024
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
15 November 2024
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degener
01 November 2024
Long-Acting Degradable Implants for Endometriosis Treatment
01 November 2024
First-ever long-acting injectable for malaria prevention administered to study volunteer
01 November 2024
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema\n
04 October 2024
UNAIDS response to Gilead’s announcement on signing voluntary licensing agreements on lenacapavir with six generic manufacturers
04 October 2024
Newer stories
Older Stories